Recent News

• 04.24.2025 - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
• 04.22.2025 - HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
• 03.21.2025 - HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
• 03.20.2025 - Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
• 03.20.2025 - HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
• 03.19.2025 - HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
• 03.19.2025 - HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Recent Filings

• 04.22.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.22.2025 - EX-99.1 EX-99.1
• 04.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.31.2025 - EX-99.1 EX-99.1
• 03.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.20.2025 - EX-99.1 EX-99.1
• 03.19.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.19.2025 - EX-99.1 EX-99.1